View Future GrowthPharmagreen Biotech 과거 순이익 실적과거 기준 점검 0/6Pharmagreen Biotech은 연평균 66.4%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 9.7%의 비율로 증가했습니다. 매출은 연평균 29.1%의 비율로 감소했습니다.핵심 정보66.44%순이익 성장률73.95%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률-29.10%자기자본이익률n/a순이익률-7,536.88%최근 순이익 업데이트31 Dec 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Dec 04Pharmagreen Biotech Inc. Files Form 15Pharmagreen Biotech Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common under the Securities Exchange Act of 1934, as amended.공시 • May 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/12/2023, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Feb 09Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement ProductPharmagreen Biotech Inc., announced that it has completed development of its first formulated nutraceutical product and has commenced online sales via the Shopify ecommerce platform of its MaxGenomic™ Supplement. The company is also pleased to have entered the nutraceutical industry with this product development and be part of this multi-hundred-billion-dollar industry that is growing at a record pace. MaxGenomic™ Supplement comes in a bottle with 60 Enteric capsules (delayed release), for a one- or two-month supply, depending on suggested use. This all-natural product utilizes a combination of fifteen ingredients from medicinal plants and medicinal mushrooms. Pharmagreen’s proprietary blend is unique to the market, by combining mushrooms and herbs in one, delayed release, capsule. A nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to help and assist with repairing damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. Pharmagreen’s team focus is to help and aid, in the sales of MaxGenomic™ Supplement and additional nutraceutical products development. The company has plans to keep adding to the list of honorary sports ambassadors’ representatives. Pharmagreen’s near future plans also include launching additional products of its MaxGenomic™ brand designed for the extremely active, sports professionals and on the go individuals who are looking for immediate help and support before they begin and during their routine.공시 • Dec 29Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/28/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Sep 09Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product LaunchPharmagreen Biotech Inc. announced that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen’s proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to repair damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. This product, and new products as they become available, can be purchased through the Company's soon to be launched online store, Shopify, Amazon and other third-party online outlets. Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.공시 • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Feb 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/14/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 17Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/16/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/14/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Feb 18Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp BiomassPharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of higher quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required. Pharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of highest quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required.공시 • Feb 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/12/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Dec 30Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/29/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.매출 및 비용 세부 내역Pharmagreen Biotech가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:PHBI 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 24000030 Sep 240-10030 Jun 24000031 Mar 240-10031 Dec 230-10030 Sep 230-10030 Jun 230-11031 Mar 23001031 Dec 220-11030 Sep 220-11030 Jun 220-21031 Mar 220-21031 Dec 210-41030 Sep 210-51030 Jun 210-51031 Mar 210-60031 Dec 200-30030 Sep 200-20030 Jun 200-20031 Mar 20001031 Dec 190-11030 Sep 190-11030 Jun 19001031 Mar 190-11031 Dec 180-11030 Sep 180-110양질의 수익: PHBI 은(는) 현재 수익성이 없습니다.이익 마진 증가: PHBI는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 PHBI의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PHBI의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PHBI은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PHBI의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 15:24종가2026/05/22 00:00수익2024/12/31연간 수익2024/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharmagreen Biotech Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Dec 04Pharmagreen Biotech Inc. Files Form 15Pharmagreen Biotech Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common under the Securities Exchange Act of 1934, as amended.
공시 • May 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/12/2023, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Feb 09Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement ProductPharmagreen Biotech Inc., announced that it has completed development of its first formulated nutraceutical product and has commenced online sales via the Shopify ecommerce platform of its MaxGenomic™ Supplement. The company is also pleased to have entered the nutraceutical industry with this product development and be part of this multi-hundred-billion-dollar industry that is growing at a record pace. MaxGenomic™ Supplement comes in a bottle with 60 Enteric capsules (delayed release), for a one- or two-month supply, depending on suggested use. This all-natural product utilizes a combination of fifteen ingredients from medicinal plants and medicinal mushrooms. Pharmagreen’s proprietary blend is unique to the market, by combining mushrooms and herbs in one, delayed release, capsule. A nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to help and assist with repairing damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. Pharmagreen’s team focus is to help and aid, in the sales of MaxGenomic™ Supplement and additional nutraceutical products development. The company has plans to keep adding to the list of honorary sports ambassadors’ representatives. Pharmagreen’s near future plans also include launching additional products of its MaxGenomic™ brand designed for the extremely active, sports professionals and on the go individuals who are looking for immediate help and support before they begin and during their routine.
공시 • Dec 29Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/28/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Sep 09Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product LaunchPharmagreen Biotech Inc. announced that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen’s proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to repair damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. This product, and new products as they become available, can be purchased through the Company's soon to be launched online store, Shopify, Amazon and other third-party online outlets. Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
공시 • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Feb 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/14/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 17Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/16/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 15Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 05/14/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Feb 18Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp BiomassPharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of higher quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required. Pharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of highest quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required.
공시 • Feb 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 02/12/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Dec 30Pharmagreen Biotech Inc. announced delayed annual 10-K filingOn 12/29/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 13Pharmagreen Biotech Inc. announced delayed 10-Q filingOn 08/12/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.